Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen-Deprivation Therapy

European Urology, Supplements

Volumn 7, Issue 1, 2008, Pages 15-21

  Tombal, Bertrand ^a   Berges, Richard ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b PAN Klinik am Neumarkt   (Germany)

Author keywords

Eligard; Hormone therapy; Leuprorelin; Luteinising hormone releasing hormone agonist; Prostate cancer; Testosterone

Indexed keywords

ANTIANDROGEN; FOLLITROPIN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

BONE DENSITY; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR RISK; CASTRATION; DIABETES MELLITUS; DISEASE EXACERBATION; DISTRESS SYNDROME; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EXTERNAL BEAM RADIOTHERAPY; HEART DEATH; HEART INFARCTION; HIP FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; ORCHIECTOMY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SIDE EFFECT; VERTEBRA FRACTURE;

EID: 37249009591     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.11.001     Document Type: Review

References (43)

1. Huggins C. Endocrine-induced regression of cancers. Nobel Lecture available on http://nobelprize.org/nobel_prizes/medicine/laureates/1996/huggins-lecture.html.
2. Oefelein M.G., and Resnick M.I. Effective testosterone suppression for patients with prostate cancer: is there a best castration?. Urology 62 (2003) 207-213
3. Studer U.E., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24 (2006) 1868-1876
4. Studer U.E., Collette L., Whelan P., et al. Which subgroups of patients with newly diagnosed T0-4 N0-2 M0 prostate cancer not suitable for local treatment with curative intent (EORTC 30891) are at risk to die from prostate cancer and benefit from immediate androgen deprivation?. Eur Urol Suppl 6 (2007) 27 (abstract no. 19)
5. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
6. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-108
7. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
8. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
9. Joon D.L., Hasegawa M., Sikes C., et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38 (1997) 1071-1077
10. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
11. Bolla M., van Tienhoven G., de Reijke T.M., et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT - results of the randomized EORTC Phase III trial 22961. J Clin Oncol 25 Suppl. (2007) 238S (abstract no. 5014)
12. D'Amico A.V., Loffredo M., Renshaw A.A., Loffredo B., and Chen M.H. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol 24 (2006) 4190-4195
13. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
14. Alibhai S.M., Gogov S., and Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60 (2006) 201-215
15. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
16. Holmes-Walker D.J., Woo H., Gurney H., Do V.T., and Chipps D.R. Maintaining bone health in patients with prostate cancer. Med J Aust 184 (2006) 176-179
17. Moyad M.A. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol 23 (2005) 56-64
18. Oefelein M.G., Feng A., Scolieri M.J., Ricchiutti D., and Resnick M.I. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56 (2000) 1021-1024
19. Rohl H.F., and Beuke H.P. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 26 (1992) 11-14
20. Kaisary A.V., Tyrrell C.J., Peeling W.B., and Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 67 (1991) 502-508
21. Lin B.J.T., Chen K.K., Chen M.T., and Chang L.S. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology 43 (1994) 834-837
22. Vogelzang N.J., Chodak G.W., Soloway M.S., et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 46 (1995) 220-226
23. Tombal B., Jasienski S., Debie B., Salvado Besnier J.A., and Van Cangh P. Is there a significant difference in testosterone level after surgical castration, goserelin or triptorelin?. Eur Urol Suppl 6 (2007) 87 (abstract no. 260)
24. Schally A.V., Kastin A.J., and Arimura A. Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. Fertil Steril 22 (1971) 703-721
25. Coy D., Vilchez-Martinez J.A., Coy E., Arimura A., and Schally A.V. A peptide inhibitor of luteinizing hormone-releasing hormone (LH-RH). J Clin Endocrinol Metab 37 (1973) 331-333
26. http://www.uroweb.org/nc/professional-resources/guidelines/online/. Accessed 2007.
27. Pathak A.S., Pacificar J.S., Shapiro C.E., and Williams S.G. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J Urol 177 (2007) 2132-2135
28. Morote J., Esquena S., Abascal J.M., et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 77 (2006) 135-138
29. Sarosdy M.F., Schellhammer P.F., Soloway M.S., et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 83 (1999) 801-806
30. Oefelein M.G., and Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164 (2000) 726-729
31. McLeod D., Zinner N., Tomera K., et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58 (2001) 756-761
32. Wechsel H.W., Zerbib M., Pagano F., and Coptcoat M.J. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 30 Suppl. 1 (1996) 7-14
33. Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int 60 Suppl. 2 (1998) 18-24
34. Kawakami J., and Morales A. A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists. J Urol 167 Suppl. (2002) 288 (abstract no. 1135)
35. Khan M.S., and O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 60 (1998) 33-40
36. Fontana D., Mari M., Martinelli A., et al. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int 70 (2003) 316-320
37. Sharifi R., and Browneller R. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 168 (2002) 1001-1004
38. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 19 (2001) 3750-3757
39. Schulman C. Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int 100 Suppl. 1 (2007) 6-11
40. Ravivarapu H.B., Moyer K.L., and Dunn R.L. Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate. J Pharm Sci 89 (2000) 732-741
41. Crawford E.D., Sartor O., Chu F., et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 175 (2006) 533-536
42. Perez-Marreno R., Chu F.M., Gleason D., et al. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 24 (2002) 1902-1914
43. Chu F.M., Jayson M., Dineen M.K., et al. A clinical study of 22.5 mg. LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 168 (2002) 1199-1203